$Dupilumab for cancer-associated refractory pruritus$

Dupilumab for cancer-associated refractory pruritus

Background: Pruritus can be an intolerable symptom in patients with cancer. Type 2 inflammation, and specifically, the cytokines IL-4, IL-13, and IL-31, play major roles in the itching process. Dupilumab is an antibody against IL-4Rα, which is a common IL-4 and IL-13 receptor subunit. Blocking IL-4...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính:	Aviv Talmon, MD, Shlomo Elias, MD, PhD, Limor Rubin, MD, Yaarit Ribak, MD, Eyal Ben Dori, MD, Oded Shamriz, MD, Michal Lotem, MD, Irit Adini, PhD, Yuval Tal, MD, PhD
Định dạng:	Bài viết
Ngôn ngữ:	English
Được phát hành:	Elsevier 2023-08-01
Loạt:	Journal of Allergy and Clinical Immunology: Global
Những chủ đề:	Oncologic pruritus chronic pruritus itch IL-4 IL-13 IL-31
Truy cập trực tuyến:	http://www.sciencedirect.com/science/article/pii/S277282932300053X

Internet

http://www.sciencedirect.com/science/article/pii/S277282932300053X

Dupilumab for cancer-associated refractory pruritus

Internet

Những quyển sách tương tự